Table 1.
Study design features in SABINA I and II
| SABINA I (UK) | SABINA II | ||||
|---|---|---|---|---|---|
| Germany | Italy | Sweden | Spain | ||
| Data source | Primary care records (CPRD GOLD), linked with secondary care (HES) and mortality (ONS) data | IMS® Disease Analyzer: electronic medical records from general practitioner and pulmonologist panels | IQVIA® databases: electronic medical records from primary care (Longitudinal Patient Database) and secondary care (Patient Analyzer) physicians | Nationwide longitudinal cohort study (HERA): linked data from national patient, pharmacy dispensing, and mortality registries | BIG-PAC® database: electronic medical records from primary and specialized healthcare |
| Study period | 2007–2017 | 2013–2018 | 2015–2018 | 2006–2016 | 2017–2018 |
| Age | ≥ 12 years | ≥ 12 years | ≥ 12 years | 12–45 years | ≥ 12 years |
| Asthma definition | Asthma diagnosis code within 3 years of index date | Asthma diagnosis code during study period | Asthma diagnosis code 1 year prior to index date | ≥ 2 collections for a chronic obstructive pulmonary disease medication within 12 months | Asthma diagnosis code and ≥ 2 healthcare uses within study period |
| Asthma treatment steps | 2016 BTS guidelines | 2018 GINA recommendations | 2018 GINA recommendations | 2018 GINA recommendations | 2018 GINA recommendations |
BTS British Thoracic Society, CPRD Clinical Practice Research Datalink, GINA Global Initiative for Asthma, HERA High Efficiency Reliable Access (to data stores), HES Hospital Episode Statistics, ONS Office for National Statistics, SABINA SABA use IN Asthma